204 related articles for article (PubMed ID: 26901566)
1. Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.
Dotan I; Roche PJ; Paliouras M; Mitmaker EJ; Trifiro MA
PLoS One; 2016; 11(2):e0149723. PubMed ID: 26901566
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.
Liu TR; Su X; Qiu WS; Chen WC; Men QQ; Zou L; Li ZQ; Fu XY; Yang AK
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3582-91. PubMed ID: 27649658
[TBL] [Abstract][Full Text] [Related]
3. Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.
Zhang J; Zhao A; Jia X; Li X; Liang Y; Liu Y; Xie X; Qu X; Wang Q; Zhang Y; Gao R; Yu Y; Yang A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142613
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.
Li H; Zhou X; Wang G; Hua D; Li S; Xu T; Dong M; Cui X; Yang X; Wu Y; Cai M; Liao X; Zhang T; Yang Z; Du Y; Li X
J Clin Endocrinol Metab; 2022 Mar; 107(4):1110-1126. PubMed ID: 34751400
[TBL] [Abstract][Full Text] [Related]
5. TSHR rs2288496 associated with thyroid hormone and predict the occurrence of lymph node metastasis of papillary thyroid cancer.
Su X; Lin LW; Weng JL; Chen SW; Yang XH; Zhou DL; Long YK; Shao Q; Ye ZL; Peng JL; Deng L; He CY; Yang AK
Cancer Biomark; 2019; 26(4):461-470. PubMed ID: 31658048
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
7. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
[TBL] [Abstract][Full Text] [Related]
8. CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA.
Aliyev A; Gupta M; Nasr C; Hatipoglu B; Milas M; Siperstein A; Berber E
Endocr Pract; 2015 Jul; 21(7):777-81. PubMed ID: 25786552
[TBL] [Abstract][Full Text] [Related]
9. Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.
Rosario PW; Siman TL; Calsolari MR
Endocrine; 2015 May; 49(1):170-4. PubMed ID: 25209895
[TBL] [Abstract][Full Text] [Related]
10. Circulating Epithelial Cell Characterization and Correlation with Remission and Survival in Patients with Thyroid Cancer.
Lin JD; Liou MJ; Hsu HL; Leong KK; Chen YT; Wang YR; Hung WS; Lee HY; Tsai HJ; Tseng CP
Thyroid; 2018 Nov; 28(11):1479-1489. PubMed ID: 30221579
[TBL] [Abstract][Full Text] [Related]
11. P21-activated kinase 4 involves TSH induced papillary thyroid cancer cell proliferation.
Xie X; Shi X; Guan H; Guo Q; Fan C; Dong W; Wang G; Li F; Shan Z; Cao L; Teng W
Oncotarget; 2017 Apr; 8(15):24882-24891. PubMed ID: 28178642
[TBL] [Abstract][Full Text] [Related]
12. Papillary thyroid cancer: medical management and follow-up.
Kloos RT
Curr Treat Options Oncol; 2005 Jul; 6(4):323-38. PubMed ID: 15967085
[TBL] [Abstract][Full Text] [Related]
13. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.
He H; Li W; Liyanarachchi S; Jendrzejewski J; Srinivas M; Davuluri RV; Nagy R; de la Chapelle A
J Clin Endocrinol Metab; 2015 Jan; 100(1):E164-72. PubMed ID: 25303483
[TBL] [Abstract][Full Text] [Related]
14. Exosomes Expressing Thyrotropin Receptor Attenuate Autoantibody-Mediated Stimulation of Cyclic Adenosine Monophosphate Production.
Edo N; Kawakami K; Fujita Y; Morita K; Uno K; Tsukamoto K; Onose H; Ishikawa T; Ito M
Thyroid; 2019 Jul; 29(7):1012-1017. PubMed ID: 31062662
[No Abstract] [Full Text] [Related]
15. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.
So YK; Son YI; Baek CH; Jeong HS; Chung MK; Ko YH
Ann Surg Oncol; 2012 Mar; 19(3):990-5. PubMed ID: 21879263
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors.
Hoffmann S; Hofbauer LC; Scharrenbach V; Wunderlich A; Hassan I; Lingelbach S; Zielke A
J Clin Endocrinol Metab; 2004 Dec; 89(12):6139-45. PubMed ID: 15579770
[TBL] [Abstract][Full Text] [Related]
17. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
[TBL] [Abstract][Full Text] [Related]
18. Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.
Gimblet GR; Whitt J; Houson HA; Lin D; Guenter R; Rao TC; Wang D; Ness J; Gonzalez ML; Murphy MS; Gillis A; Chen H; Copland JA; Kenderian SS; Lloyd RV; Szkudlinski MW; Lapi SE; Jaskula-Sztul R
Surgery; 2024 Jan; 175(1):199-206. PubMed ID: 37919223
[TBL] [Abstract][Full Text] [Related]
19. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
20. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
